Drug Development

Share SHARE

FDA-091614.jpg The FDA has issued its approval on a new constipation drug from Nektrar Pharma and AstraZeneca. The new drug, called Movantik (naloxegol), is aimed at reducing the constipation associated with opioid pain killers without reducing the central pain killing effects. It is the first drug in its class approved by the FDA and is likely to hit the market two to three years before any competing drugs.

AlzheimerAssociation-040611.jpg A new study suggests that older adults who regularly use sedatives for anxiety or insomnia may have a heightened risk of developing Alzheimer's disease. The drugs in question are benzodiazepines, sedatives that include lorazepam (Ativan), diazepam (Valium) and alprazolam (Xanax). The study, published online in journal BMJ, examined the histories of nearly 1,800 older adults with Alzheimer's.

Ruxolitinib-081914.jpg A drug that is commonly used to treat bone marrow cancer may help to restore hair in patients with an autoimmune disease that causes hair loss, a new study has found. The study, published online August 17 in the journal Nature Medicine, found that the drug ruxolitinib (brand name: Jakafi) helped to restore hair growth in a small number of patients with alopecia areata.